BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20008917)

  • 1. Can tumor necrosis factor inhibitors be safely used in pregnancy?
    Ali YM; Kuriya B; Orozco C; Cush JJ; Keystone EC
    J Rheumatol; 2010 Jan; 37(1):9-17. PubMed ID: 20008917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
    Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
    Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
    Skomsvoll JF; Wallenius M; Koksvik HS; Rødevand E; Salvesen KA; Spigset O; Kvien TK
    Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF; Sanchez-Yamamoto D; Bush TM
    J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
    Katz JA; Antoni C; Keenan GF; Smith DE; Jacobs SJ; Lichtenstein GR
    Am J Gastroenterol; 2004 Dec; 99(12):2385-92. PubMed ID: 15571587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety assessment of tumor necrosis factor antagonists during pregnancy.
    Osting VC; Carter JD
    Expert Opin Drug Saf; 2010 May; 9(3):421-9. PubMed ID: 20367495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
    Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
    J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide.
    Gluck PA; Gluck JC
    Curr Med Res Opin; 2005 Jul; 21(7):1075-84. PubMed ID: 16004676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship.
    Carter JD; Valeriano J; Vasey FB
    J Rheumatol; 2006 May; 33(5):1014-7. PubMed ID: 16652431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utilization of atypical antipsychotics in pregnancy and lactation.
    Gentile S
    Ann Pharmacother; 2004; 38(7-8):1265-71. PubMed ID: 15150376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.
    Carter JD; Ladhani A; Ricca LR; Valeriano J; Vasey FB
    J Rheumatol; 2009 Mar; 36(3):635-41. PubMed ID: 19132789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy.
    Williams M; Chakravarty EF
    Curr Opin Rheumatol; 2014 May; 26(3):341-6. PubMed ID: 24663107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A; Greenberg JD
    Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis and reproduction.
    Golding A; Haque UJ; Giles JT
    Rheum Dis Clin North Am; 2007 May; 33(2):319-43, vi-vii. PubMed ID: 17499710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
    Liang GC; Cordero M; Dyer A; Chang RW
    J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.